It has previously been shown that IL-2/JES6 immunocomplexes potently expand Treg cells in vivo and that they can be used for treatment of various autoimmune diseases (Liu et al., 2011; Webster et al., 2009; Wilson et al., 2008). Here, IL2 is linked to autoimmune disease.